rs370240037

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.

The NM_000051.4(ATM):​c.1440A>C​(p.Leu480Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000589 in 1,614,080 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000062 ( 0 hom. )

Consequence

ATM
NM_000051.4 missense

Scores

1
6
12

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:11

Conservation

PhyloP100: -0.0620
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 0 ACMG points.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ATMNM_000051.4 linkc.1440A>C p.Leu480Phe missense_variant Exon 10 of 63 ENST00000675843.1 NP_000042.3 Q13315A0A024R3C7

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ATMENST00000675843.1 linkc.1440A>C p.Leu480Phe missense_variant Exon 10 of 63 NM_000051.4 ENSP00000501606.1 Q13315

Frequencies

GnomAD3 genomes
AF:
0.0000328
AC:
5
AN:
152218
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000199
AC:
5
AN:
251354
Hom.:
0
AF XY:
0.0000221
AC XY:
3
AN XY:
135842
show subpopulations
Gnomad AFR exome
AF:
0.0000615
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000264
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000616
AC:
90
AN:
1461862
Hom.:
0
Cov.:
36
AF XY:
0.0000536
AC XY:
39
AN XY:
727230
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000800
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
AF:
0.0000328
AC:
5
AN:
152218
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74366
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000735
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000386
Hom.:
0
Bravo
AF:
0.0000113
TwinsUK
AF:
0.00
AC:
0
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.0000165
AC:
2

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Ataxia-telangiectasia syndrome Uncertain:3
Dec 10, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 480 of the ATM protein (p.Leu480Phe). This variant is present in population databases (rs370240037, gnomAD 0.004%). This missense change has been observed in individual(s) with ATM-related conditions (PMID: 19638463, 24448499, 26580448, 28779002, 33436325, 36029002). ClinVar contains an entry for this variant (Variation ID: 186322). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt ATM protein function with a negative predictive value of 95%. Experimental studies have shown that this missense change affects ATM function (PMID: 36029002). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Jul 30, 2020
Natera, Inc.
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 13, 2017
Counsyl
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Uncertain:2
Sep 09, 2024
Ambry Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.L480F variant (also known as c.1440A>C), located in coding exon 9 of the ATM gene, results from an A to C substitution at nucleotide position 1440. The leucine at codon 480 is replaced by phenylalanine, an amino acid with highly similar properties. This alteration has been identified in multiple individuals diagnosed with breast and/or ovarian cancer (Kanchi KL et al. Nat. Commun. 2014;5:3156; Lu C et al. Nat Commun. 2015 Dec 22;6:10086; Decker B et al. J. Med. Genet., 2017 11;54:732-741). This alteration has also been identified in multiple individuals diagnosed with prostate cancer (Matejcic M et al. JCO Precis Oncol, 2020 Jan;4:32-43; Karlsson Q et al. Eur Urol Oncol, 2021 Aug;4:570-579). This alteration was This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -

Oct 17, 2022
Color Diagnostics, LLC DBA Color Health
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This missense variant replaces leucine with phenylalanine at codon 480 of the ATM protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with ovarian cancer (PMID: 24448499, 26689913), chronic lymphocytic leukemia (PMID: 36029002), prostate cancer (PMID: 19638463, 33436325), and breast cancer (PMID: 28779002, 33471991). In a case-control study conducted in the UK, this variant was reported in 2/13087 breast cancer cases and 1/5488 controls (PMID: 28779002). In a second case-control study with international participation, this variant was reported in 3/60463 breast cancer cases and 2/53459 controls (PMID: 33471991). This variant has been identified in 6/282752 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

not specified Uncertain:1
Jan 06, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: ATM c.1440A>C (p.Leu480Phe) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 252468 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1440A>C has been reported in the literature in individuals affected with prostate cancer and individuals affected with other types of cancer (e.g. Pugh_2009, Karlsson_2021, Kanchi_2014, Lu_2015, Zhang_2015, Petrackova_2022). These reports do not provide unequivocal conclusions about association of the variant with prostate cancer or other ATM-related cancers. At least one publication reports experimental evidence evaluating the effect of the variant on protein function in CLL and T cells from an individual with chronic lymphocytic leukaemia who had the variant in the germline (Petrackova_2022). The most pronounced variant effect resulted in >50%-80% ATM activity versus the wildtype protein. The following publications have been ascertained in the context of this evaluation (PMID: 24448499, 33436325, 26689913, 19638463, 26580448, 36029002). ClinVar contains an entry for this variant (Variation ID: 186322). Based on the evidence outlined above, the variant was classified as uncertain significance. -

Breast and/or ovarian cancer Uncertain:1
May 11, 2022
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
Apr 03, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

ATM-related disorder Uncertain:1
May 28, 2024
PreventionGenetics, part of Exact Sciences
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

The ATM c.1440A>C variant is predicted to result in the amino acid substitution p.Leu480Phe. This variant has been observed in an individual with ovarian cancer who also harbored a loss of function variant in the BRCA1 gene (Kanchi et al. 2014. PubMed ID: 24448499) and another individual with prostate cancer (Pugh et al. 2009. PubMed ID: 19638463). This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD and is interpreted as uncertain in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/186322/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

not provided Uncertain:1
Jul 29, 2024
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Observed in individuals with ovarian, breast, or prostate cancer (PMID: 19638463, 24448499, 26689913, 28779002, 32832836, 33436325); This variant is associated with the following publications: (PMID: 19638463, 26689913, 24448499, 28779002, 26580448, 32832836, 33436325, 36029002, 33471991) -

Familial cancer of breast Uncertain:1
Feb 05, 2024
Baylor Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.037
T
BayesDel_noAF
Benign
-0.11
CADD
Benign
17
DANN
Uncertain
1.0
DEOGEN2
Benign
0.096
.;T;T
Eigen
Benign
-0.0091
Eigen_PC
Benign
-0.18
FATHMM_MKL
Benign
0.13
N
LIST_S2
Benign
0.81
T;T;.
M_CAP
Benign
0.056
D
MetaRNN
Uncertain
0.43
T;T;T
MetaSVM
Benign
-0.71
T
MutationAssessor
Uncertain
2.7
.;M;M
PrimateAI
Uncertain
0.51
T
PROVEAN
Benign
-2.2
N;N;N
REVEL
Uncertain
0.31
Sift
Uncertain
0.014
D;D;D
Sift4G
Pathogenic
0.0
D;D;D
Polyphen
1.0
.;D;D
Vest4
0.85, 0.81
MutPred
0.31
Gain of MoRF binding (P = 0.1027);Gain of MoRF binding (P = 0.1027);Gain of MoRF binding (P = 0.1027);
MVP
0.89
MPC
0.60
ClinPred
0.92
D
GERP RS
-3.1
Varity_R
0.22
gMVP
0.34

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs370240037; hg19: chr11-108121632; API